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Abstract
Introduction Total mesorectal excision (TME) is an
essential component of surgical management of rectal
cancer. Both open and laparoscopic TME have been proven
to be oncologically safe. However, it remains a challenge
to achieve complete TME with clear circumferential
resections margin (CRM) with the conventional transab-
dominal approach, particularly in mid and low rectal
tumours. Transanal TME (TaTME) was developed to
improve oncological and functional outcomes of patients
with mid and low rectal cancer.
Methods An international, multicentre, superiority, ran-
domised trial was designed to compare TaTME and con-
ventional laparoscopic TME as the surgical treatment of
mid and low rectal carcinomas. The primary endpoint is
involved CRM. Secondary endpoints include completeness
of mesorectum, residual mesorectum, morbidity and mor-
tality, local recurrence, disease-free and overall survival,
percentage of sphincter-saving procedures, functional out-
come and quality of life. A Quality Assurance Protocol
including centralised MRI review, histopathology re-eval-
uation, standardisation of surgical techniques, and moni-
toring and assessment of surgical quality will be conducted.
Discussion The difference in involvement of CRM between
the two treatment strategies is thought to be in favour of the
TaTME. TaTME is therefore expected to be superior to
laparoscopic TME in terms of oncological outcomes in case of
mid and low rectal carcinomas.
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Annually approximately 737.000 patients are diagnosed
with rectal cancer worldwide [1]. The standard potentially
curative treatment of rectal cancer is total mesorectal
excision (TME). With the introduction of laparoscopic
TME, concerns arose about the oncological safety. The
COlorectal cancer Laparoscopic or Open Resection
(COLOR) II trial demonstrated improved short-term out-
comes and similar long-term outcomes after laparoscopic
resection of rectal cancer, compared with open resection
[2, 3].
However, particularly resection of mid and low rectal
cancer is technically demanding due to tapering of the
mesorectum in the pelvis and the forward angle of the
distal rectum rendering this part of the rectum less acces-
sible from the abdominal cavity. These factors predispose
to incomplete mesorectal excision and involved circum-
ferential resection margins (CRMs), with consequent local
recurrences. Moreover, high morbidity rates are reported as
result of poor anastomotic techniques and high conversion
rates because of the limited view on the distal margin of the
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tumour and difficult mobilisation in the narrow pelvis.
Despite the increasing uptake of laparoscopic TME in the
treatment of rectal cancer, conversion rates to open pro-
cedures are reported up to 34 % [2, 4, 5]. Conversion is
frequently needed in male, obese patients or in case of
bulky or distally located tumours. Furthermore, mid and
low rectal cancer surgery is associated with poor functional
outcome with high colostomy rates compared to high rectal
cancer [2]. Large randomised trials reported rates of
abdominoperineal resection (APR) in laparoscopic rectal
cancer resection of 25–29 % [2, 4].
To improve visualisation and potentially improve
functional and oncological results, the transabdominal
transanal (TATA) technique was introduced in the 1990’s,
which included an open approach from below to rectal
tumours located in the distal one-third of the rectum [6].
The use of single port laparoscopic platforms has enabled
the introduction of transanal TME (TaTME) by Lacy in
2010. Both techniques have in common to adhere to TME
principles, achieving tumour-free distal and circumferential
margins (CRMs) and harvesting a minimum of 12 lymph
nodes for pathological assessment [7]. The TaTME tech-
nique takes the most important developments in rectal
cancer surgery from the last 30 years and combines them
into one surgical technique [8].
TaTME for mid and low rectal cancer has potential
benefits: better specimen quality with better radicality, less
morbidity as result of better anastomotic techniques and
less conversions and more sphincter-saving rectal resec-
tions without compromising oncological outcomes.
Several groups have already demonstrated that TaTME
can be performed safely with a promising amount of intact
specimens and low rates of involved CRM [9–14]. The
next crucial step of assessing a surgical innovation is a
randomised controlled trial. Therefore, a randomised trial
is needed to evaluate the role of TaTME in rectal cancer
and to assess oncological outcomes. The COLOR III trial
has been designed to compare short- and long-term out-
comes of transanal and laparoscopic TME for mid and low
rectal cancer.
Patients and methods
COLOR III trial is an international, multicentre, superior-
ity, randomised trial comparing TaTME and laparoscopic
TME as the surgical treatment of mid and low rectal
carcinomas.
Eligibility
A total of 1098 consecutive patients scheduled for resec-
tion of a solitary mid or low rectal carcinoma (5–10 and
0–5 cm from anal verge on MRI) will be included in the
COLOR III trial. Patients with stage I–III rectal cancer for
whom TME is indicated, suitable for elective resection,
with a rectal carcinoma observed at colonoscopy and his-
tologically proven through biopsy are eligible. The distal
border of the tumour has to be within 10 cm of the anal
verge on MRI scan. A CT scan of the thorax and abdomen
should be performed to exclude distant metastases. Patients
after neoadjuvant therapy, patients with any BMI, as well
as patients with previous abdominal or pelvic surgery can
be included. Furthermore, patients with tumours that are
downstaged can be included. This means patients with a
distance of\2 mm between tumour and mesorectal fascia,
tumour ingrowth in the anal sphincter complex or m.
levator ani or T4 tumours having: distance more than 2 mm
between tumour and mesorectal fascia, no ingrowth or no
T4 tumour after neoadjuvant therapy can be included.
Informed consent will be obtained from all eligible patients
in accordance with the requirements of the local ethical
board.
Exclusion criteria are T1 tumours which can be treated
by local excision, T3 tumours with margins\1 mm to the
endopelvic fascia, tumours with ingrowth in the internal
sphincter or m. levator ani and all T4 tumours as staged
through MRI scan prior to neoadjuvant therapy. Other
causes for exclusion are previous rectal surgery, pregnancy,
age \18 years, absolute contraindications to general
anaesthesia or prolonged pneumoperitoneum (ASA score
of more than III), signs of acute intestinal obstruction or
synchronous abdominal surgery. Furthermore, a medical
history of familial adenomatous polyposis coli, hereditary
non-polyposis colorectal cancer, active Crohn’s disease or
colitis ulcerosa or other malignancies, except adequately
treated basocellular skin carcinoma or in situ cervix uteri
carcinoma, will result in exclusion.
All participating centres in the COLOR III trial will
keep the coordinating centre informed of all patients pre-
senting with rectal cancer. Data on patients with rectal
cancer who are not included in the COLOR III trial will be
registered.
Randomisation
Once eligibility has been established, patient details have
been noted and the preoperative MRI is centrally reviewed,
patients will be allocated to either transanal or laparoscopic
TME. Randomisation will be performed by computer
through the internet and will be stratified for preoperative
(chemo)radiotherapy, T-stage, height of the tumour (mid or
low) and gender. Patients will be randomised in a 2:1 ratio,
in favour of the TaTME. Data will be analysed on ‘inten-
tion to treat’ basis in case patients are not subjected to the
randomised treatment modality.
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Surgical procedure
Included surgical procedures to obtain TME are: 1. low
anterior resection (LAR) with colorectal anastomosis, 2.
LAR with coloanal anastomosis and 3. intersphincteric
abdominoperineal resection (APR).
Excluded is an extralevator abdominoperineal excision
(ELAP) (indicated in patients with tumour ingrowth in the
anal sphincter complex or m. levator ani).
Complete laparoscopic excision of the total mesorectum
is mandatory to qualify the procedure as a ‘laparoscopic
TME’. The level of transection of the inferior mesenteric
artery is up to the surgeon’s preference. Both right and left
hypogastric nerves should be preserved. The splenic flex-
ure should be mobilised when undue tension at the anas-
tomosis is likely. Other aspects of the surgical procedure
such as type of anastomosis, use of diverting ileostomy and
drainage of surgical field are up to the discretion of the
surgeon.
In TaTME, the rectum is being mobilised transanally
according to TME principles. TaTME is defined as dis-
section of the distal one-third of the mesorectum. After
resection of the rectum and the mesorectum, a hand sewed
or stapled anastomosis is created according to the prefer-
ence of the performing surgeon, as well as creation of a
diversion ileostomy and drainage of the surgical field.
In both treatment arms, the use of single port as well as
multiport laparoscopy is allowed for the abdominal part of
the procedure. Robotic TME is not allowed, since robotic
TME possibly results in different primary and secondary
endpoint results compared with laparoscopic TME.
In TaTME, conversion (to either laparoscopic or open
TME) is defined as interruption of transanal TME due to
technical difficulties or complications during transanal
dissection, requiring completion of the majority of the
TME using an abdominal approach. In laparoscopic TME,
conversion is defined when completion of the dissection of
the mesorectum is performed through a traditional open
abdominal or transanal approach. Conversion is determined
by the surgeon in case of concerns about patient safety,
technical difficulties and inability to complete the TME
procedure adequately or associated conditions that require
treatment.
COLOR III trial quality assurance
To ensure both surgical quality and centre capability to
adhere to the study protocol, including the recruitment
process and data collection, the COLOR III trial Quality
Assurance Protocol has been developed and will be applied
before entering into the trial.
To evaluate surgical quality, a Quality Assurance
Manual and a Competency Assessment Tool for technical
and oncological quality for laparoscopic and TaTME
within the scope of COLOR III have been developed.
These will be used for surgeon selection into the trial and to
measure adherence to agreed surgical quality standards
during the trial. A Delphi methodology has been applied
with a peer-nominated international group of expert col-
orectal consultants in the TaTME technique in order to
develop a technical manual and operation logbook.
A TaTME Competency Assessment Tool was developed
based on the results of the Delphi methodology. This tool
has been validated in order to ensure acceptable reliability
and validity standards prior to its implementation in the
pre-trial and main trial phases.
A sign-off/sign-in process is included in the COLOR III
trial in order to evaluate each centre’s capability to (i) re-
cruit and randomise patients, (ii) comply with the treatment
protocol and (iii) collect required data. Centres that wish to
participate in COLOR III trial will be required to recruit
and randomise 5 patients following the study protocol. A
pre-trial checklist will be used to measure the compliance.
If a centre is unsuccessful in completing the Trial
Quality Assurance Procedure, the evidence will be
reviewed by the COLOR III steering committee and more
evidence will be required for the component that is
unsatisfactory. Within the scope of Surgical Quality
Assurance, surgeons will be required to gain more expe-
rience with the support from COLOR III expert group and
re-assessed.
The data collected during this Trial Quality Assurance
Phase will not contribute to the main trial.
Before the trial entry, each surgeon will be required to
submit 2 unedited videos for both laparoscopic and trans-
anal TME. Two reviewers will assess the videos indepen-
dently using the Competency Assessment Tool as the pre-
trial entry procedure. During the main trial period, each
surgeon will be required to submit 1 unedited video for
every 3 cases for both laparoscopic and TaTME. The
videos will be assessed using the Competency Assessment
Tool to monitor the adherence to agreed standards.
Follow-up
Follow-up will be carried out (according to ESMO guide-
lines) yearly for a period of 5 years at the outpatient clinic
(Fig. 1) [15]. More frequent visits and additional exami-
nation will be performed on indication or to the preference
of the attending surgeon. Three years post-operatively, an
MRI of the pelvis will be performed to exclude local
recurrence. A chest radiograph and a liver ultrasound or CT
scan of thorax and abdomen will be done to assess any
development of distant metastases. Recurrences and deaths
should be reported to the coordinating centre through the
COLOR III online platform or telephone within 2 weeks of
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detection. Follow-up of patients with recurrent disease will
be continued until at least 3 years after detection or until
death. Post-operative health-related quality of life (quality-
adjusted life years) and functional outcome will be evalu-
ated at 1, 3, 6, 12, 24 and 36 months post-operatively
(measured with EORTC QLQ-CR29 and C30, EQ-5D and
LARS questionnaires).
Endpoints
The primary endpoint of this trial is involvement of CRM.
The CRM is deemed involved if malignant cells are found
at microscopical assessment within 1 mm between the
outermost part of the tumour and the CRM or between
lymph nodes bearing tumour cells and the CRM. Second-
ary endpoints include completeness of mesorectum, resid-
ual mesorectum, morbidity and mortality, local recurrence,
disease-free and overall survival, percentage of sphincter-
saving procedures, functional outcome and quality of life.
Statistical analysis
Involved CRM in laparoscopic TME for mid and low rectal
carcinomas is estimated to be 7 %. The primary objective
of the trial is to demonstrate a reduction in 4 % of involved
CRM after TaTME compared to laparoscopic TME. To
demonstrate a difference of 4 % (7–3 %) at a randomisa-
tion ratio of 2:1, 732 TaTME patients and 366 laparoscopic
TME patients are required for inclusion to generate a
power of 80 % for this trial. Baseline numerical data will
be described in means, standard deviations or medians and
interquartile ranges; baseline categorical data will be
displayed in percentages. All comparative analyses will be
conducted on an ‘intention to treat’ basis. Consequently,
patients who are randomised to TaTME and converted to a
laparoscopic or open TME will be analysed in the TaTME
group. Patients who are randomised to a laparoscopic
resection and converted to TaTME or open TME will be
analysed in the laparoscopic group. Ninety days post-
operative mortality, pathological resection margin and
complication rates will be compared using the Chi-square
test or an exact test if necessary. Local recurrence rate,
disease-free and overall survival will be compared using
the log-rank test. Exploratory analysis of the prognostic
effects of various baseline factors on disease-free survival
will be carried out through multivariate Cox regression.
Apart from intention to treat analyses, per protocol analy-
ses will be applied.
Accrual and limitations
For inclusion of 1098 patients, approximately 4 years are
needed. Because at the start of the trial accrual will be
limited to the main centres, the estimated accrual per year
will be as follows:
Year 1: 108 patients (5 hospitals, approximately 2
patients per month)
Year 2: 290 patients (15 hospitals, approximately 1–2
patients per month)
Year 3: 300 patients (25 hospitals, approximately 1–2
patients per month)
Year 4: 400 patients (30 hospitals, approximately 1–2
patients per month)
Fig. 1 Follow-up scheme
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Centralising MRI review will not be limitation of this
study, because MRIs will be uploaded through an online
tool and can be reviewed the same day.
Monitoring, audit and inspection
Governors will be appointed to monitor trial progress on
site, as frequently as seen necessary. The medical ethical
review board of the coordinating centre (VU University
Medical Centre) will register the trial at the Clinical
Research Bureau (CRB). The CRB will assign a data safety
monitoring board (DSMB) to the trial. Interim analysis will
not be performed, because the classification of this trial is
not high risk. The DSMB will review the collected data and
results.
Trial registration
The trial will be registered at http://clinicaltrials.gov.
Discussion
Worldwide, colorectal cancer is the third most common
malignancy in males after prostate and lung cancer and the
second most common malignancy in females after breast
cancer. Each year, colorectal cancer afflicts approximately
737.000 new patients and causes about 333.000 deaths in
developed countries [1]. For curative therapy, surgical
intervention is required.
Rectal cancer surgery is generally considered techni-
cally more challenging than colon surgery, mainly because
of the limited workspace in the small pelvis. In particular,
in mid and low rectal tumours it is more difficult to achieve
a radical resection because of this limited workspace and
moreover due to limited visualisation. In addition, patients
are confronted with high morbidity rates due to poor
anastomotic techniques and conversion. Furthermore, mid
and low rectal cancer surgery is associated with higher
rates of permanent colostomies compared with surgery for
high rectal cancer.
A quality indicator for rectal cancer surgery is the CRM.
An involved CRM of 2 mm or\2 mm is associated with a
local recurrence risk of 16 % compared with 5.8 % in
patients without involvement of CRM (p\ 0.0001) [16].
Various large randomised controlled trials reported an
involved CRM in 7.7–16 % of patients operated because
rectal cancer and higher rates of involved CRM were
reported in distal rectal tumours compared to mid and
proximal rectal tumours [4, 16–18].
To overcome the lack of visibility in the small pelvis
and theoretically improve the rate of radical resections and
decrease the rate of involved CRMs, Lacy et al. [9]
introduced a transanal approach for TME in 2010. The
TaTME has been developed with use of laparoscopic single
port platforms to improve the quality of the TME proce-
dure in mid and low rectal cancer. In TaTME, the tumour is
distally approached through the anus with laparoscopic
instruments. This facilitates a high-quality dissection of the
distal mesorectum with adequate visual determination of
the distal resection margin. The excellent view potentially
enables nerve-sparing and sphincter-saving rectal excision.
From 2010 to date, several cohort series have been
published regarding hybrid endoscopic TaTME. These
series suggest that TaTME is feasible and safe regarding
short-term outcomes and delivers high-quality resection
specimen in selected patients. The series that excluded T4
tumours have demonstrated a promising CRM involvement
of 0–5.4 % [10–13]. The largest series, including 140
patients, reported CRM involvement of 6.4 %; however,
T4 tumours were not excluded and all patients with
involvement of CRM were correctly predicted by MRI.
Short-term morbidity and oncological results were com-
parable to other laparoscopic TME series [14]. A ran-
domised controlled trial is required to evaluate the role of
TaTME for rectal cancer and to assess oncological out-
comes on the long term.
Before adaptation of TaTME as standard surgical therapy
for mid and low rectal cancer, a well-designed study is
essential to demonstrate its efficacy and safety in a multi-
centre randomised setting: COLOR III trial. The primary
concern is oncological safety in terms of CRM involvement
and local recurrence rate. Secondary concerns are safety in
terms of morbidity and functional outcome. Furthermore, a
major challenge in surgical cancer clinical trials is lack of
consistency in surgical quality. This study aims at addressing
this limitation by applying a robust surgical Quality Assur-
ance Protocol prior to the start and throughout the clinical
trial to ensure consistency and validity.
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